

PATENT APPLICATION U.S. Appln. No. 10/580,050 International Application No. PCT/US04/39333 Attorney Docket No. PP021454.0004

Express Mail Label No.: EM 028421462US Date: March 20, 2009

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

In Re Application of: Qui-Lim Choo

U.S. Appln. No.: 10/580,050

Intl. Appln. No.: PCT/US04/39333

I.A. Filing Date: 11/19/2004

Priority Date: 11/19/2003

Title: METHODS AND REAGENTS FOR

TREATING, PREVENTING AND DIAGNOSING BUNYAVIRUS

INFECTION

Confirmation No.: 7391

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", mailed February 18, 2009 from the United States Patent and Trademark Office. The applicant would like advise the USPTO that a Preliminary Amendment with a Sequence Listing was filed January 31, 2008. We are re-submitting the Preliminary Amendment and Sequence Listing to comply with Notice. Enclosed herewith are the following documents to complete the "Notice to Comply

PATENT APPLICATION U.S. Appln. No. 10/580,050 International Application No. PCT/US04/39333 Attorney Docket No. PP021454,0004

with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" in the above-identified application:

- 1. COPY OF Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
- 2. PRELIMINARY AMENDMENT.
- 3. TRANSMITTAL OF SEQUENCE LISTING INCLUDING:
 - a. Statements Under 37 C.F.R. 1.821(f-g), including statement specifically directing entry of the sequence listing into the application.
 - b. Paper Copy of the Sequence Listing (60 pages).
 - c. Compact Disk Containing CRF Copy of Sequence Listing (1 CD).
- 4. EXECUTED DECLARATIONS (6 PAGES).
- 5. RETURN RECEIPT POSTCARD.

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment associated with this communication and which may be required under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Regina Bautista

Registration No. 46,280

Customer No. 27476


NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Corporate Intellectual Property - R338

P.O. Box 8097

Emeryville, CA 94662-8097

Telephone: (510) 923-2192 Facsimile: (510) 655-3542



CONFIRMATION NO. 7391 371 FORMALITIES LETTER

0000000034583749

Date Mailed: 02/18/2009

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to comply with the sequence rules, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filling a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

• A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html


page 1 of 2

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

INDIA	LEV	ANS

Telephone: (703) 308-9140 EXT 212



Letter Regarding a New Notice and/or the Status of the Application

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 01/16/2007. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

DOCKETED on/by 2/23/91 06

Aity. RSB PA

File # 51835- 43-PO

Due Date Ext

Final Date 4/18/09

Prop 1454 Octory

page 1 of 1